
    
      Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with
      placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors
      for thrombosis.

      Randomization 1:1 - Group 1 will receive Apixaban 2.5mg twice daily vs. matching placebo
      (Group 2) for 30 days.

      Primary Objective: To evaluate the clinical impact of a strategy of oral anticoagulation with
      apixaban comparing with placebo on the number of days alive and out of the hospital/emergency
      department (DAOH) through 30 days in outpatients with symptomatic SARS-CoV2 infection and
      risk factors for thrombosis.
    
  